KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Steris (STE) Other financing activities (2018 - 2025)

Steris has reported Other financing activities over the past 8 years, most recently at -$16.9 million for Q4 2025.

  • Quarterly results put Other financing activities at -$16.9 million for Q4 2025, down 5733.33% from a year ago — trailing twelve months through Dec 2025 was -$16.9 million (down 186.95% YoY), and the annual figure for FY2025 was $2.5 million, changed.
  • Other financing activities for Q4 2025 was -$16.9 million at Steris, down from $7.6 million in the prior quarter.
  • Over the last five years, Other financing activities for STE hit a ceiling of $16.6 million in Q3 2024 and a floor of -$16.9 million in Q4 2025.
  • Median Other financing activities over the past 5 years was $1.2 million (2022), compared with a mean of $700578.9.
  • Biggest five-year swings in Other financing activities: crashed 7125.64% in 2023 and later skyrocketed 1017.09% in 2024.
  • Steris' Other financing activities stood at -$13.7 million in 2021, then skyrocketed by 100.29% to $39000.0 in 2022, then crashed by 7125.64% to -$2.7 million in 2023, then surged by 110.95% to $300000.0 in 2024, then crashed by 5733.33% to -$16.9 million in 2025.
  • The last three reported values for Other financing activities were -$16.9 million (Q4 2025), $7.6 million (Q3 2025), and $9.3 million (Q2 2025) per Business Quant data.